<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive bladder cancer - Lai, LY - 2022 | Cochrane Library</title> <meta content="Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive bladder cancer - Lai, LY - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014887.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive bladder cancer - Lai, LY - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014887.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014887.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive bladder cancer" name="citation_title"/> <meta content="Lillian Y Lai" name="citation_author"/> <meta content="University of Michigan" name="citation_author_institution"/> <meta content="lilliala@med.umich.edu" name="citation_author_email"/> <meta content="Sean M Tafuri" name="citation_author"/> <meta content="California Northstate University" name="citation_author_institution"/> <meta content="Emily C Ginier" name="citation_author"/> <meta content="University of Michigan" name="citation_author_institution"/> <meta content="Lindsey A Herrel" name="citation_author"/> <meta content="University of Michigan" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Philipp Maisch" name="citation_author"/> <meta content="Giulia Ippolito Lane" name="citation_author"/> <meta content="University of Michigan" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD014887.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/04/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014887.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014887.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014887.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cystoscopy; Narrow Band Imaging [methods]; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; *Urinary Bladder Neoplasms [diagnostic imaging, drug therapy, surgery]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014887.pub2&amp;doi=10.1002/14651858.CD014887.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014887\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014887\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","th","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014887.pub2",title:"Narrow band imaging versus white light cystoscopy alone for transurethral resection of non\\u2010muscle invasive bladder cancer",firstPublishedDate:"Apr 8, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014887.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014887.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014887.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014887.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014887.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014887.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014887.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014887.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014887.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014887.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1682 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014887.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/appendices#CD014887-sec-0086"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/table_n/CD014887StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/table_n/CD014887StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive bladder cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#CD014887-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Lillian Y Lai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#CD014887-cr-0005">Sean M Tafuri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#CD014887-cr-0006">Emily C Ginier</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#CD014887-cr-0007">Lindsey A Herrel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#CD014887-cr-0008">Philipp Dahm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#CD014887-cr-0009">Philipp Maisch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information#CD014887-cr-0010">Giulia Ippolito Lane</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information/en#CD014887-sec-0100">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 April 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014887.pub2">https://doi.org/10.1002/14651858.CD014887.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014887-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014887-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014887-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014887-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014887-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014887-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD014887-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014887-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014887-abs-0001" lang="en"> <section id="CD014887-sec-0001"> <h3 class="title" id="CD014887-sec-0001">Background</h3> <p>Disease recurrence and progression remain major challenges for the treatment of non‐muscle invasive bladder cancer. Narrow band imaging (NBI) is an optical enhancement technique that may improve resection of non‐muscle invasive bladder cancer and thereby lead to better outcomes for people undergoing the procedure.  </p> </section> <section id="CD014887-sec-0002"> <h3 class="title" id="CD014887-sec-0002">Objectives</h3> <p>To assess the effects of NBI‐ and white light cystoscopy (WLC)‐guided transurethral resection of bladder tumor (TURBT) compared to WLC‐guided TURBT in the treatment of non‐muscle invasive bladder cancer. </p> </section> <section id="CD014887-sec-0003"> <h3 class="title" id="CD014887-sec-0003">Search methods</h3> <p>We performed a comprehensive literature search of 10 databases, including the Cochrane Library, the Cochrane Database of Systematic Reviews, MEDLINE, Embase, several clinical trial registries, and grey literature for published and unpublished studies, irrespective of language. The search was performed per an a priori protocol on 3 December 2021. </p> </section> <section id="CD014887-sec-0004"> <h3 class="title" id="CD014887-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials of participants with suspected or confirmed non‐muscle invasive bladder cancer. Participants in the control group must have received WLC‐guided TURBT alone (hereinafter simply referred to as 'WLC TURBT'). Participants in the intervention group had to have received NBI‐ and WLC‐guided TURBT (hereinafter simply referred to as 'NBI + WLC TURBT'). </p> </section> <section id="CD014887-sec-0005"> <h3 class="title" id="CD014887-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies for inclusion/exclusion, performed data extraction, and assessed risk of bias. We conducted meta‐analysis on time‐to‐event and dichotomous data using a random‐effects model in RevMan, according to Cochrane methods. We rated the certainty of evidence for each outcome according to the GRADE approach. </p> <p>Primary outcomes were time to recurrence, time to progression, and the occurrence of a major adverse event, defined as a Clavien‐Dindo III, IV, or V complication. Secondary outcomes included time to death from bladder cancer and the occurrence of a minor adverse event, defined as a Clavien‐Dindo I or II complication.  </p> </section> <section id="CD014887-sec-0006"> <h3 class="title" id="CD014887-sec-0006">Main results</h3> <p>We included eight studies with a total of 2152 participants randomized to the standard WLC TURBT or to NBI + WLC TURBT. A total of 1847 participants were included for analysis.  </p> <p>Based on limited confidence in the time‐to‐event data, we found that NBI + WLC TURBT may lower the risk of disease recurrence over time compared to WLC TURBT (hazard ratio 0.63, 95% CI 0.45 to 0.89; I<sup>2</sup> = 53%; 6 studies, 1244 participants; low certainty of evidence). No studies examined disease progression as a time‐to‐event outcome or a dichotomous outcome. There may be little to no difference in the risk of a major adverse event between participants who underwent NBI + WLC TURBT and those who underwent WLC TURBT (risk ratio 1.77, 95% CI 0.79 to 3.96; 4 studies, 1385 participants; low certainty of evidence). </p> <p>No studies examined death from bladder cancer as a time‐to‐event outcome or a dichotomous outcome. There may be little to no difference in the risk of a minor adverse event between participants who underwent NBI + WLC TURBT and those who underwent WLC TURBT (risk ratio 0.88, 95% CI 0.49 to 1.56; I<sup>2</sup> = 61%; 4 studies, 1385 participants; low certainty of evidence).  </p> </section> <section id="CD014887-sec-0007"> <h3 class="title" id="CD014887-sec-0007">Authors' conclusions</h3> <p>Compared to WLC TURBT alone, NBI + WLC TURBT may lower the risk of disease recurrence over time while having little or no effect on the risks of major or minor adverse events.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014887-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014887-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014887-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014887-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014887-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014887-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD014887-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014887-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD014887-abs-0016">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD014887-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014887-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014887-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014887-abs-0002" lang="en"> <h3>Comparing narrow band imaging to regular cystoscopy for treatment of bladder cancer</h3> <p><b>Review question</b> </p> <p>How does a resection of bladder tissues guided by a special visualization method called narrow band imaging compare to a resection of bladder tissues guided by the standard visualization method (using white light) in people with tumors in their inner bladder wall? </p> <p><b>Background</b> </p> <p>When people are suspected to have bladder cancer or have been diagnosed with bladder cancer, their doctors need to inspect the bladder closely and remove tissues for further examination. The removal of tumorous tissues also serves as treatment. The procedure to remove tumors in the bladder is called transurethral resection of bladder tumor, or TURBT. TURBT is done by passing a special instrument through the urethra and into the bladder. Sometimes, it is difficult to distinguish healthy normal bladder tissue from tumorous tissue. Some doctors use a special visualization method known as narrow band imaging to help visualize the tumorous tissues. </p> <p><b>Study characteristics</b> </p> <p>We analyzed data from published studies called randomized controlled trials to understand if narrow band imaging reduces the risk of bladder cancer getting worse, and to see if there are any side effects. We only included randomized controlled trials because this study type is the most reliable. </p> <p><b>Key results</b> </p> <p>We identified eight randomized controlled trials that addressed our review question. Participants included in these studies were suspected to have bladder cancer or were diagnosed with bladder cancer that was limited to the inner wall, meaning that the cancer did not invade the underlying muscle layers. Based on limited available data, the use of narrow band imaging may lower the risk of disease recurrence over time. </p> <p>None of the randomized controlled trials examined whether the choice of visualization method made any difference to the risk of bladder cancer becoming worse or the risk of the person dying from bladder cancer, so we do not know if the use of narrow band imaging is effective in improving these two outcomes.  </p> <p>We found that the use of narrow band imaging may have little or no increased risk of complications, compared to the standard visualization method. </p> <p><b>Quality of the evidence</b> </p> <p>Due to certain flaws in the design of these clinical trials and some contradictory findings between trials, our confidence in these findings was low. With more research in the future, more reliable data may likely change these findings. The evidence is up to date to December 2021. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014887-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014887-sec-0081"></div> <h3 class="title" id="CD014887-sec-0082">Implications for practice</h3> <section id="CD014887-sec-0082"> <p>White light cystoscopy (WLC)‐ and narrow band imaging (NBI)‐guided transurethral resection of bladder tumor (TURBT) may lower the risk of disease recurrence over time compared to WLC TURBT in the treatment of non‐muscle invasive bladder cancer. Overall, our confidence in the effect estimates is limited. The true effects on disease recurrence may be substantially different from the effect estimates.   </p> <p>Unfortunately, no studies analyzed the effect of NBI + WLC TURBT on the risk of disease progression or bladder cancer death. In terms of patient safety, NBI + WLC TURBT may have little to no effect on major or minor adverse effects, though we have low confidence in the effect estimates. </p> <p>However, unlike blue light cystoscopy, NBI + WLC TURBT does not require instillation of photosensitizing agents into the bladder. Further, given that many cystoscopes can be switched from the white light mode to the NBI mode with no significant interruption to the procedural workflow, NBI + WLC TURBT may be considered as an additional intervention to improve outcomes.  </p> </section> <h3 class="title" id="CD014887-sec-0083">Implications for research</h3> <section id="CD014887-sec-0083"> <p>The review identified only eight randomized controlled trials addressing certain aspects of the research question. The certainty of evidence was low. This underscores the importance of following higher methodological standards for designing trials, registering and peer reviewing trial protocols a priori, and using CONSORT guidelines when reporting trial results.  </p> <p>Further, few studies presented time‐to‐event data. While we were able to mitigate this limitation by using established methods to calculate time‐to‐event data, this additional calculation might have introduced bias in our results. When reporting time‐to‐event data, trialists may also consider including numbers at risk in their graphs or as supplementary data for improving data transparency. Standardizing data reporting and collection would facilitate additional systematic reviews and improve the quality of meta‐analyses. Future studies may also consider examining the effectiveness of WLC TURBT alone versus NBI + WLC TURBT for surveillance of people with non‐muscle invasive bladder cancer.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014887-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014887-sec-0008"></div> <div class="table" id="CD014887-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">NBI + WLC TURBT compared to WLC TURBT for transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NBI + WLC TURBT compared to WLC TURBT for transurethral resection of bladder tumors in people with non‐muscle invasive bladder cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer<br/><b>Setting:</b> outpatient or inpatient setting<br/><b>Intervention:</b> NBI + WLC TURBT<br/><b>Comparison:</b> WLC TURBT  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with WLC TURBT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with NBI + WLC TURBT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Time to disease recurrence</b> </p> <p> </p> <p>Follow‐up: range 12 months to 35 months</p> <p> </p> <p>Assumed MCID: 5% (absolute effect size estimate based on events at 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>1244<br/>(6 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.63<br/>(0.45 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In the low risk population, NBI + WLC TURBT may lower the risk of disease recurrence over time. We have limited confidence about this finding. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 fewer per 1000<br/>(79 fewer to 15 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>In the high risk population, NBI + WLC TURBT may lower the risk of disease recurrence over time. We have limited confidence about this finding. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>610 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 fewer per 1000<br/>(265 fewer to 43 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to disease progression</b>  </p> <p> </p> <p>Follow‐up: not applicable</p> <p> </p> <p>Assumed MCID: 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no data on time to disease progression.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse event</b> (Clavien‐Dindo grade III, IV, and V) </p> <p> </p> <p>Follow‐up: range 3 months to 24 months</p> <p> </p> <p>Assumed MCID: 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1385<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.77<br/>(0.79 to 3.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NBI + WLC TURBT may have little to no effect on major adverse events. We have limited confidence about this finding. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 more per 1000<br/>(3 fewer to 39 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to death from bladder cancer</b> </p> <p> </p> <p>Follow‐up: not applicable</p> <p> </p> <p>Assumed MCID: 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no data on time to death from bladder cancer.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse event</b> (Clavien‐Dindo grade I and II) </p> <p> </p> <p>Follow‐up: range 3 months to 24 months</p> <p> </p> <p>Assumed MCID: 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1385<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.49 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NBI + WLC TURBT may have little to no effect on the risk of a minor adverse event. We have limited confidence about this finding. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 fewer per 1000<br/>(58 fewer to 63 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MCID:</b> minimal clinically important difference; <b>NBI:</b> narrow band imaging; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>TURBT:</b> transurethral resection of bladder tumor; <b>WLC:</b> white light cystoscopy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We rated down by one level for study limitations due to unclear or high risk of bias.<br/><sup>b</sup>We rated down by one level for imprecision given few events, wide confidence intervals, or both.<br/><sup>c</sup>The recurrence rate after TURBT for participants with non‐muscle invasive bladder cancer is highly variable in the literature. Among the pooled cohort of 2596 participants from seven European Organization for Research and Treatment of Cancer clinical trials, the probabilities of recurrence at one year after TURBT ranged from 15% to 61% (<a href="./references#CD014887-bbs2-0057" title="SylvesterRJ , van derMeijdenAP , OosterlinckW ,  WitjesJA , BouffiouxC , DenisL , et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology2006;49(3):466-77. [DOI: 10.1016/j.eururo.2005.12.031]">Sylvester 2006</a>). Therefore, we considered 15% as low risk and 61% as high risk.  </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014887-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014887-sec-0009"></div> <section id="CD014887-sec-0010"> <h3 class="title" id="CD014887-sec-0010">Description of the condition</h3> <p>Bladder cancer is the tenth most common malignancy and the second most common urologic malignancy worldwide, with an estimated 550,000 new cases and 200,000 deaths per year (<a href="./references#CD014887-bbs2-0026" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA .Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians2018;68(6):394‐424. [DOI: 10.3322/caac.21492]">Bray 2018</a>). Specifically, urothelial carcinoma accounts for 90% of all bladder cancers in the USA and Europe. Smoking contributes to 50% to 65% of all bladder cancer cases, increasing the risk of disease by up to four‐fold (<a href="./references#CD014887-bbs2-0031" title="FreedmanND , SilvermanDT , Hollenbeck AR, SchatzkinA , AbnetCC .Association between smoking and risk of bladder cancer among men and women. JAMA2011;306(7):737-45.">Freedman 2011</a>). Additional risk factors include environmental and occupational exposure to chemical carcinogens such as aromatic amines, and treatment of leukemia and lymphoma with cyclophosphamide (<a href="./references#CD014887-bbs2-0027" title="ChangSS , BoorjianSA , ChouR , ClarkPE , DaneshmandS , KonetyBR , et al.Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Joint Guideline.. Journal of Urology2016;196:1021-9.">Chang 2016</a>). </p> <p>People with bladder cancer most often present with blood in their urine, but tumors can also be found during the evaluation for other symptoms, such as irritative voiding symptoms. The prevalence of bladder cancer ranges between 13% and 35% in people presenting with macroscopic hematuria and between 5% and 10% in those with microscopic hematuria (<a href="./references#CD014887-bbs2-0056" title="SunM , TrinhQD .Diagnosis and staging of bladder cancer. Hematology/oncology Clinics of North America2015;29(2):205-18.">Sun 2015</a>). People with bladder tumors then proceed to undergo transurethral resection of bladder tumor (TURBT), where tumorous tissues are removed for staging and treatment. </p> <p>Pathologists classify tumors based on cell histology and the depth of invasion into the layers of the bladder wall (in order of depth: mucosa, lamina propria, and muscle layers). The majority of bladder cancers present as superficial tumors that do not invade the underlying bladder muscle at diagnosis. These superficial tumors are referred to as non‐muscle invasive bladder cancer, and have a 60% to 70% risk of recurrence (<a href="./references#CD014887-bbs2-0024" title="AldousariS , KassoufW .Update on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal2010;4(1):56-64.">Aldousari 2010</a>). Histologic characteristics can also predict the risk of progression. In general, papillary tumors on the mucosa of the bladder (Ta) are indolent, whereas the subset of superficial tumors called carcinoma in situ (CIS or Tis), and tumors that invade to the lamina propria layer (T1), are considered more aggressive and of concern for progression to muscle invasive disease (<a href="./references#CD014887-bbs2-0041" title="HumphreyPA , MochH , CubillaAL , UlbrightTM , ReuterVE .The 2016 WHO classification of tumours of the urinary system and male genital organs – Part B. Prostate and bladder tumours. European Urology2016;70(1):106-19. [DOI: 10.1016/j.eururo.2016.02.028]">Humphrey 2016</a>). </p> <p>Once non‐muscle invasive bladder cancer invades the muscle layers, the disease is referred to as muscle invasive bladder cancer. Muscle invasive bladder cancer is associated with high rates of morbidity and mortality, and its treatment approach is highly invasive (<a href="./references#CD014887-bbs2-0056" title="SunM , TrinhQD .Diagnosis and staging of bladder cancer. Hematology/oncology Clinics of North America2015;29(2):205-18.">Sun 2015</a>). As bladder cancer progresses, the survival rate drops significantly. Within the USA, the five‐year survival rate for people with carcinoma in situ is 95.8%; for those with localized disease confined to primary site, it is 69.2%; for those with regional disease with spread of disease to regional lymph nodes, it is 36.5%; and for those with metastatic disease, it is 5.5% (<a href="./references#CD014887-bbs2-0054" title="Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute.Cancer Stat Facts: Bladder Cancer. seer.cancer.gov/statfacts/html/urinb.html (accessed 15 September 2020).">SEER 2020</a>).   </p> </section> <section id="CD014887-sec-0011"> <h3 class="title" id="CD014887-sec-0011">Description of the intervention</h3> <p>Traditionally, TURBT is performed using white light cystoscopy (WLC). During this procedure, experienced urologists visually distinguish conspicuous lesions from normal mucosa. However, complete identification and removal of tumors during TURBT can be challenging, as the sensitivity of WLC ranges from 62% to 84% for identifying bladder tumors, and the specificity ranges from 43% to 98% (<a href="./references#CD014887-bbs2-0056" title="SunM , TrinhQD .Diagnosis and staging of bladder cancer. Hematology/oncology Clinics of North America2015;29(2):205-18.">Sun 2015</a>). The sensitivity of WLC is particularly low for small or flat lesions that are visually subtle or difficult to differentiate from areas of inflammation. Consequently, some recurrences can be attributable to, if not entirely consisting of, lesions left behind due to incomplete resection (<a href="./references#CD014887-bbs2-0057" title="SylvesterRJ , van derMeijdenAP , OosterlinckW ,  WitjesJA , BouffiouxC , DenisL , et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology2006;49(3):466-77. [DOI: 10.1016/j.eururo.2005.12.031]">Sylvester 2006</a>). On second‐look TURBT using WLC, the residual tumor rate was reported to be as high as 43% to 62% (<a href="./references#CD014887-bbs2-0032" title="GohAC , Lerner SP.Application of new technology in bladder cancer diagnosis and treatment. World Journal of Urology2009;27(3):301-7.">Goh 2009</a>). Given these limitations, additional technologies are needed to augment the visual detection of tumors in the lower urinary tract. One such technology is narrow band imaging (NBI).  </p> <p>The NBI setting on the cystoscope changes the optical filters used to visualize the bladder, resulting in an image that may potentially improve visualization of tumors. At the time of the TURBT, urologists can toggle between white light and NBI using camera setting buttons, to help identify tumors.  </p> </section> <section id="CD014887-sec-0012"> <h3 class="title" id="CD014887-sec-0012">How the intervention might work</h3> <p>The working principle of NBI relies on two phenomena. First, hemoglobin characteristically absorbs blue light at 415 nm and green light at 540 nm (<a href="./references#CD014887-bbs2-0055" title="SrivastavaR .History and physics of narrow band imaging. In: Atlas on Narrow Band Imaging in Upper Aerodigestive Tract Lesions. Singapore: Springer, 2019:7-10.">Srivastava 2019</a>). NBI uses optical filters to narrow the bandwidth of white light, such that only blue and green light pass through. NBI light is then preferentially absorbed by vessels, and reflected by mucosa. Second, the depth of light penetration into tissues depends on wavelength; the shorter the wavelength, the more superficial the penetration. The shorter NBI light wavelength only penetrates the superficial layers of the mucosa. Together, the differential absorption and penetration enhance the visibility of surface capillaries and blood vessels in the submucosa.  </p> <p>Under NBI mode, tumors with richer vasculature appear dark green or black in a background of normal urothelium, which appears mostly white (<a href="./references#CD014887-bbs2-0049" title="NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Narrow band imaging for detecting residual/recurrent cancerous tissue during second transurethral resection of newly diagnosed non-muscle-invasive high-grade bladder cancer. British Journal of Urology International2009;105(2):208-11.">Naselli 2009</a>). In contrast, lesions appear red under white light mode against the normal urothelium, which appears pink. Because tumors have more blood vessels than normal mucosa, NBI can potentially improve visualization of lesions that are difficult to see, and delineation of tumor margins, which together can enable more thorough tumor excision. </p> <p>The impact of NBI on time‐to‐disease recurrence outcomes may not only be in the primary detection and resection of tumors, but also due to the fact that increased detection and resection of tumors may impact the individual's risk stratification and lead to more aggressive observation and intervention schedules (<a href="./references#CD014887-bbs2-0027" title="ChangSS , BoorjianSA , ChouR , ClarkPE , DaneshmandS , KonetyBR , et al.Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Joint Guideline.. Journal of Urology2016;196:1021-9.">Chang 2016</a>). Therefore, the benefit (or harm) of NBI + WLC TURBT may be compounded due to the impact of the intervention on subsequent patient care.  </p> <p>In contrast to blue light cystoscopy, another form of optical enhancement technology (<a href="./references#CD014887-bbs2-0047" title="MaischP , KoziarzA , VajgrtJ , NarayanV , KimMH , DamnP .Blue versus white light for transurethral resection of non-muscle invasive bladder cancer. Cochrane Database of Systematic Reviews2021, Issue 12. Art. No: CD013776. [DOI: 10.1002/14651858.CD013776.pub2]">Maisch 2021</a>), NBI does not require any chemical to function. Moreover, systems integrating WLC and NBI are readily available (<a href="./references#CD014887-bbs2-0049" title="NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Narrow band imaging for detecting residual/recurrent cancerous tissue during second transurethral resection of newly diagnosed non-muscle-invasive high-grade bladder cancer. British Journal of Urology International2009;105(2):208-11.">Naselli 2009</a>). The NBI mode on a cystoscope can be activated with a control button, without adding significant risks or interruptions to the flow of the procedure. </p> <section id="CD014887-sec-0013"> <h4 class="title">Adverse effects of the intervention</h4> <p>NBI highlights areas of increased blood vessels, which is a surrogate for a potential tumor. The technology does not specifically identify tumors. The increased sensitivity compounded by decreased specificity may increase false positive rates. This can lead to more extensive resection and over‐treatment, increasing the risk of bleeding or complications, such as bladder perforation. Also, NBI cannot be used when there is active bleeding, since blood can absorb NBI light and obstruct visibility. </p> </section> </section> <section id="CD014887-sec-0014"> <h3 class="title" id="CD014887-sec-0014">Why it is important to do this review</h3> <p>The impact of NBI during TURBT remains unclear. The detection and complete resection of non‐muscle invasive bladder cancer lesions are central to the treatment of the disease. Optical advances, such as NBI, offer the potential to improve clinicians’ ability to detect tumors. However, the effect of NBI on decreasing recurrence and progression is not well assessed. </p> <p>Currently, the American Urological Association/Society of Urologic Oncology guideline suggests a conditional recommendation for the use of NBI + WLC TURBT (<a href="./references#CD014887-bbs2-0027" title="ChangSS , BoorjianSA , ChouR , ClarkPE , DaneshmandS , KonetyBR , et al.Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Joint Guideline.. Journal of Urology2016;196:1021-9.">Chang 2016</a>). While the European Association of Urology acknowledges that NBI may improve cancer detection, its guideline states that evidence for potential reductions in recurrence rate is limited (<a href="./references#CD014887-bbs2-0025" title="BabjukM , BurgerM , CompératE , GonteroP , MostafidHA , PalouJ , et al.European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. European Urology2019;76(5):639-57.">Babjuk 2019</a>). Meanwhile, the National Institute for Health and Care Excellence guideline suggests that NBI may be offered to people with suspected bladder cancer in conjunction with WLC TURBT (<a href="./references#CD014887-bbs2-0050" title="NICE. Bladder cancer: diagnosis and management NICE guideline [NG2]. Published date: 25 February 2015; Updated April 2019. Available from www.nice.org.uk (accessed 15 September 2020).">NICE 2015</a>). In this context, we conducted a stringent examination of current evidence to help inform clinicians and guideline developers on the use of NBI at time of TURBT.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014887-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014887-sec-0015"></div> <p>To assess the effects of NBI‐ and white light cystoscopy (WLC)‐guided transurethral resection of bladder tumor (TURBT) compared to WLC‐guided TURBT in the treatment of non‐muscle invasive bladder cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014887-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014887-sec-0016"></div> <section id="CD014887-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014887-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomized controlled trials, in which individual participants were randomized.  </p> <p>We excluded quasi‐experimental studies and cluster‐randomized trials due to their lack of random assignment at the individual level (<a href="./references#CD014887-bbs2-0051" title="PufferS , TorgersonDJ , WatsonJ .Cluster randomized controlled trials. Journal of Evaluation in Clinical Practice2005;11(5):479-83.">Puffer 2005</a>). We excluded cross‐over trials from our review, as both the comparator and the experimental interventions involve removal of bladder tumors. Inclusion of cross‐over trials would present a serious carry‐over effect (<a href="./references#CD014887-bbs2-0039" title="HigginsJP , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </section> <section id="CD014887-sec-0019"> <h4 class="title">Types of participants</h4> <p>We defined the eligible population as adults, aged 18 and over, with a suspected or established diagnosis of primary or recurrent urothelial carcinoma of the bladder, based on one of the following. </p> <p> <ul id="CD014887-list-0001"> <li> <p>Bladder mass or abnormal bladder mucosa findings per clinic‐based WLC</p> </li> <li> <p>Bladder mass on cross‐sectional imaging, such as bladder filling defects and hydronephrosis</p> </li> <li> <p>Positive or atypical urinary cytology</p> </li> <li> <p>Positive fluorescence in situ hybridization test</p> </li> </ul> </p> <p>We excluded participants undergoing NBI‐guided surveillance, as we were only considering the use of NBI in the treatment setting. We also excluded participants with distant metastatic disease.  </p> <p>If studies included multiple participant groups or interventions, we only included the subset of participants of interest. If multiple articles were published by the same group with the same participant cohort, we merged and analyzed relevant data from each article as one study. </p> </section> <section id="CD014887-sec-0020"> <h4 class="title">Types of interventions</h4> <p>Concomitant interventions had to be the same in the experimental and control groups to establish fair comparisons. Trials that described more than one use of NBI + WLC (for example: during subsequent cystoscopy or TURBT) were included, and this information was reported separately if available. </p> <section id="CD014887-sec-0021"> <h5 class="title">Experimental intervention</h5> <p>WLC‐ and NBI‐ guided TURBT (herein referred to as NBI + WLC TURBT)</p> </section> <section id="CD014887-sec-0022"> <h5 class="title">Comparator intervention</h5> <p>WLC‐guided TURBT (herein referred to as WLC TURBT)</p> </section> <section id="CD014887-sec-0023"> <h5 class="title">Comparison</h5> <p>NBI + WLC TURBT versus WLC TURBT in the treatment of non‐muscle invasive bladder cancer.</p> </section> </section> <section id="CD014887-sec-0024"> <h4 class="title">Types of outcome measures</h4> <p>We included studies assessing the impact of NBI + WLC TURBT on the recurrence or progression of non‐muscle invasive bladder cancer and excluded studies that reported data on NBI + WLC TURBT solely for the detection of bladder cancer.  </p> <section id="CD014887-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD014887-list-0002"> <li> <p>Time to disease recurrence (time‐to‐event outcome)</p> </li> <li> <p>Time to disease progression (time‐to‐event outcome)</p> </li> <li> <p>Major adverse event: Clavien‐Dindo grade III, IV, or V (dichotomous outcome)</p> </li> </ul> </p> </section> <section id="CD014887-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD014887-list-0003"> <li> <p>Time to death from bladder cancer (time‐to‐event outcome)</p> </li> <li> <p>Minor adverse event: Clavien‐Dindo grade I or II (dichotomous outcome)</p> </li> </ul> </p> <section id="CD014887-sec-0027"> <h6 class="title">Method and timing of outcome measurement</h6> <section id="CD014887-sec-0028"> <p><b> Primary outcomes</b></p> <p> <ol id="CD014887-list-0004"> <li> <p><b>Time to disease recurrence</b>: measured from the time of random sequence generation to time of any recurrence of bladder cancer, based on TURBT, regardless of tumor stage or grade. </p> </li> <li> <p><b>Time to disease progression</b>: measured from the time of random sequence generation to time of progression of bladder cancer as documented by histopathology. Consistent with the International Bladder Cancer Group (<a href="./references#CD014887-bbs2-0043" title="LammD , PersadR , BrausiM , BuckleyR , WitjesJA , PalouJ , et al.Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. Journal of Urology2014;191(1):20-7.">Lamm 2014</a>), we defined progression as follows. </p> <ol id="CD014887-list-0005"> <li> <p>Increase in T stage from CIS or Ta to T1</p> </li> <li> <p>Development of T2 or greater or lymph node disease or distant metastasis</p> </li> <li> <p>Increase in grade from low to high, including CIS</p> </li> </ol> </li> <li> <p><b>Major adverse event</b>: Clavien‐Dindo grade III, IV, or V (<a href="./references#CD014887-bbs2-0029" title="ClavienPA , BarkunJ , deOliveiraML , VautheyJN , DindoD , SchulickRD , et al .The Clavien-Dindo classification of surgical complications: five-year experience. Annals of Surgery2009;250(2):187-96. [DOI: 10.1097/SLA.0b013e3181b13ca2]">Clavien 2009</a>), within 90 days of TURBT </p> </li> </ol> </p> </section> <section id="CD014887-sec-0029"> <p><b>Secondary outcomes</b></p> <p> <ol id="CD014887-list-0006"> <li> <p><b>Time to death from bladder cancer</b>: measured from the time of random sequence generation to the time of death from bladder cancer. </p> </li> <li> <p><b>Minor adverse event</b>: Clavien‐Dindo grade I or II (<a href="./references#CD014887-bbs2-0029" title="ClavienPA , BarkunJ , deOliveiraML , VautheyJN , DindoD , SchulickRD , et al .The Clavien-Dindo classification of surgical complications: five-year experience. Annals of Surgery2009;250(2):187-96. [DOI: 10.1097/SLA.0b013e3181b13ca2]">Clavien 2009</a>), within 90 days of TURBT </p> </li> </ol> </p> <p>When data on the time to disease recurrence, time to disease progression, or time to death from bladder cancer were incomplete and could not be analyzed as time‐to‐event outcomes, we had planned to analyze these outcomes as dichotomous outcomes (up to 12 months, or 13 to 24 months after randomization) in efforts to increase the comprehensiveness of our analysis. This was not necessary. </p> </section> </section> <section id="CD014887-sec-0030"> <h6 class="title">Thresholds for clinical relevance of outcomes</h6> <section id="CD014887-sec-0031"> <p><b>Primary outcomes</b></p> <p> <ol id="CD014887-list-0007"> <li> <p>Time to disease recurrence: considered clinically relevant if the observed absolute difference is 5% or more at 12‐month follow‐up </p> </li> <li> <p>Time to disease progression: considered clinically relevant if the observed absolute difference is 2% or more at 12‐month follow‐up </p> </li> <li> <p>Major adverse event: considered clinically relevant if the observed absolute difference is 2% or more at initial TURBT or re‐resection </p> </li> </ol> </p> </section> <section id="CD014887-sec-0032"> <p><b>Secondary outcomes</b></p> <p> <ol id="CD014887-list-0008"> <li> <p>Time to death from bladder cancer: considered clinically relevant if the observed absolute difference is 2% or more at 12‐month follow‐up </p> </li> <li> <p>Minor adverse event: considered clinically relevant if the observed absolute difference is 5% or more at initial TURBT or re‐resection </p> </li> </ol> </p> <p>We established these thresholds based on the expert opinions of the review authors, taking into consideration the relative importance of the given outcome, and the expected control event rate.  </p> </section> </section> </section> </section> </section> <section id="CD014887-sec-0033"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted a comprehensive search, inclusive of all languages and publication statuses. We reran the search within three months prior to anticipated publication of the review. </p> <section id="CD014887-sec-0034"> <h4 class="title">Electronic searches</h4> <p>We searched for relevant studies in the following ten databases from their respective dates of inception to 14 September 2020 and 3 December 2021, using the search strategies outlined in the Appendices.  </p> <p> <ol id="CD014887-list-0009"> <li> <p>Cochrane Library (via Wiley); <a href="./appendices#CD014887-sec-0087">Appendix 1</a> </p> </li> <li> <p>International Pharmaceutical Abstracts (via Ovid); <a href="./appendices#CD014887-sec-0088">Appendix 2</a> </p> </li> <li> <p>MEDLINE (via Ovid); <a href="./appendices#CD014887-sec-0089">Appendix 3</a> </p> </li> <li> <p>Embase (via <a href="http://embase.com" target="_blank">embase.com</a>); <a href="./appendices#CD014887-sec-0090">Appendix 4</a> </p> </li> <li> <p>Web of Science Core Collection (via Clarivate); <a href="./appendices#CD014887-sec-0091">Appendix 5</a> </p> </li> <li> <p>Scopus (via Scous.com); <a href="./appendices#CD014887-sec-0092">Appendix 6</a> </p> </li> <li> <p>Latin American and Caribbean Health Science Information database (LILACS; <a href="http://lilacs.bvsalud.org/en/" target="_blank">lilacs.bvsalud.org/en/</a>) </p> </li> <li> <p>Open Grey (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>); <a href="./appendices#CD014887-sec-0093">Appendix 7</a> </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>); <a href="./appendices#CD014887-sec-0094">Appendix 8</a> </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialssearch/" target="_blank">apps.who.int/trialssearch/</a>); <a href="./appendices#CD014887-sec-0095">Appendix 9</a> </p> </li> </ol> </p> <p>We incorporated additional relevant key words found during these searches into our search strategies, and documented changes accordingly. </p> </section> <section id="CD014887-sec-0035"> <h4 class="title">Searching other resources</h4> <p>We attempted to identify other potentially eligible studies by searching the reference lists of included publications.  </p> </section> </section> <section id="CD014887-sec-0036"> <h3 class="title" id="CD014887-sec-0036">Data collection and analysis</h3> <section id="CD014887-sec-0037"> <h4 class="title">Selection of studies</h4> <p>After removing duplicate records, two review authors (LL, ST) independently scanned the titles and abstracts of studies identified by the electronic search for eligibility. The two review authors (LL, ST) screened the full‐text reports for all potentially eligible studies, according to predefined criteria. They resolved any discrepancies through consensus or arbitration of a third review author (GL). For studies identified in trial registries, we contacted the authors or institutions recorded in the registry for trial reports. We translated papers that were published in languages other than English to assess eligibility. We presented a PRISMA flowchart, showing study selection, including reasons for exclusion of studies (<a href="./references#CD014887-bbs2-0046" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]">Liberati 2009</a>). </p> </section> <section id="CD014887-sec-0038"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LL, ST or GL) conducted data extraction using an extraction form developed for this review, based on the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions </i>(<a href="./references#CD014887-bbs2-0045" title="LiT , HigginsJP , DeeksJJ , editor(s).Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Li 2020</a>). We resolved any disagreements by consensus, or by arbitration of a third review author (GL or LH) if needed. </p> <p>We extracted the following data.</p> <p> <ul id="CD014887-list-0010"> <li> <p>Study information: author, title, source, publication date, publication type, language, duplicate publications, source of funding, authors’ conflict of interest </p> </li> <li> <p>Study characteristics: study design, randomization method, number of study center(s), country of study center(s), inclusion and exclusion criteria, subgroup analysis, statistical methods, period of enrollment, follow‐up period </p> </li> <li> <p>Participants characteristics: number of participants, number of participants per study arm, age, gender, ethnicity, clinical stage of disease (presentation, focality, tumor size) </p> </li> <li> <p>Intervention and comparator information: name, frequency, duration of treatment, adjuvant therapy, re‐intervention, follow‐up </p> </li> <li> <p>Outcomes: according to the review's predefined primary and secondary outcomes (including tumor stage and grade), events of intervention and comparator groups, timing of outcome measurement, number of re‐resections </p> </li> </ul> </p> <p>We extracted the relevant outcome data needed to calculate summary statistics and measures of variance. For dichotomous outcomes, we obtained numbers of events and totals to populate a 2 x 2 table, and calculated summary statistics with corresponding measures of variance. For continuous outcomes, we obtained means and standard deviations or data necessary to calculate this information. For time‐to‐event outcomes, we extracted hazard ratios with corresponding measures of variance or data necessary to calculate this information. </p> <section id="CD014887-sec-0039"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports associated with one primary study, we maximized the yield of information by mapping all publications to a unique study ID. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD014887-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LL, ST) independently assessed the risk of bias of each included study, using the Cochrane risk of bias assessment tool (<a href="./references#CD014887-bbs2-0039" title="HigginsJP , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). They resolved disagreements by consensus, or through arbitration by a third review author (GL). We determined if risk of bias was low, high, or unclear, and presented our findings in a risk of bias summary figure. We assessed the trials for the following biases. </p> <p> <ul id="CD014887-list-0011"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>We evaluated the risk of performance bias and detection bias separately for each outcome. We grouped outcomes according to whether they were measured subjectively or objectively in the risk of bias tables. </p> <p>Performance bias ‐ susceptible</p> <p> <ul id="CD014887-list-0012"> <li> <p>We considered that all outcomes were similarly susceptible to performance bias.</p> </li> </ul> </p> <p>Detection bias ‐ susceptible</p> <p> <ul id="CD014887-list-0013"> <li> <p>Time to disease recurrence (time‐to‐event outcome)</p> </li> <li> <p>Time to disease progression (time‐to‐event outcome)</p> </li> <li> <p>Time to death from bladder cancer (time‐to‐event outcome)</p> </li> <li> <p>Minor adverse event: (Clavien‐Dindo grade I or II; dichotomous outcome)</p> </li> </ul> </p> <p>Detection bias ‐ not susceptible</p> <p> <ul id="CD014887-list-0014"> <li> <p>Major adverse event: (Clavien‐Dindo grade III, IV, or V; dichotomous outcome)</p> </li> </ul> </p> <p>We assessed Incomplete outcome data, or attrition bias, on an outcome‐specific basis. We considered the rate of attrition as low (less than 10%), unclear (between 10% and 20%), and high (20% or more). </p> <p>We assessed selective reporting bias on a study‐specific basis. We only considered the risk of selective reporting bias as low if we could identify an a priori protocol, and if the analyses and outcomes matched what the investigators preplanned. </p> <p>We summarized the risk of bias within and across outcomes and studies in graphs. We used study‐specific risk of bias assessments to inform the preplanned sensitivity analyses.  </p> </section> <section id="CD014887-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed outcomes with dichotomous data using risk ratios (RR), with 95% confidence intervals (CIs). We expressed outcomes with time‐to‐event data using hazard ratios (HR) with 95% CIs. </p> </section> <section id="CD014887-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. For studies with repeated outcome measures, we performed time‐to‐event analysis. If this was not possible, we defined outcome measures as short term (&lt; 12 months) versus long term (13 to 24 months) (<a href="./references#CD014887-bbs2-0040" title="HigginsJP , LiT , DeeksJJ , editor(s).Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> </section> <section id="CD014887-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study investigators for missing data. We only analyzed available data; we did not impute missing data. We investigated attrition rates (e.g. dropouts, losses to follow‐up, and withdrawals), and critically appraised issues of missing data and imputation methods (e.g. last observation carried forward, if used by the study authors). We addressed the impact of missing data on the findings of the review in the <a href="#CD014887-sec-0075">Discussion</a> section (<a href="./references#CD014887-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s).Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). </p> <p>We conducted intention‐to‐treat analysis whenever possible. If intention‐to‐treat analysis was not possible, we conducted as‐treated and per‐protocol population analyses. We considered this a potential source of bias. </p> </section> <section id="CD014887-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical, methodological, or statistical heterogeneity, unexplained by subgroup analyses, we planned to exclude such results from the pooled effect estimate in the meta‐analysis and provide a narrative description of the results of each study instead. </p> <p>We identified heterogeneity by assessing overlaps in CIs in forest plots. We also assessed the impact of heterogeneity on the meta‐analysis using the I² statistic (<a href="./references#CD014887-bbs2-0037" title="HigginsJP , ThompsonSG .Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [DOI: 10.1002/sim.1186]">Higgins 2002</a>; <a href="./references#CD014887-bbs2-0038" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG .Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557]">Higgins 2003</a>). We interpreted the I² statistic as follows (<a href="./references#CD014887-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s).Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). </p> <p> <ul id="CD014887-list-0015"> <li> <p>0% to 40%: may not be important</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>The importance of the observed value of the I² statistic depended on the magnitude and direction of effects, and the strength of evidence for heterogeneity. When we identified heterogeneity, we attempted to determine possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD014887-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess for selective outcome reporting. Since there were not at least 10 studies available for meta‐analysis, we could not assess for publication bias by creating and visually inspecting funnel plots. </p> </section> <section id="CD014887-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We conducted a meta‐analysis with a random‐effects model for pooling data (<a href="./references#CD014887-bbs2-0059" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , Altman DG, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5. [DOI: 10.1136/bmj.39465.451748.AD]">Wood 2008</a>). We conducted statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014887-bbs2-0045" title="LiT , HigginsJP , DeeksJJ , editor(s).Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Li 2020</a>). We analyzed dichotomous outcomes with the Mantel‐Haenszel method and continuous outcomes with the inverse variance method. We analyzed time‐to‐event outcomes using the generic inverse variance method. We used Review Manager 5 software to conduct all analyses (<a href="./references#CD014887-bbs2-0052" title="The Cochrane CollaborationReview Manager 5 (RevMan 5).Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD014887-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Certain tumor characteristics may impact outcomes. There was not sufficient data to conduct any of our preplanned subgroup analyses, listed as follows. </p> <p> <ul id="CD014887-list-0016"> <li> <p>Setting: primary versus recurrent bladder cancer</p> </li> <li> <p>Multifocality: solitary versus multiple lesions of bladder cancer</p> </li> <li> <p>Tumor size: 3 cm or less versus larger than 3 cm</p> </li> <li> <p>Stage: positive cytology, or history of carcinoma in situ (CIS; in the case of recurrent disease), or both, versus negative cytology, or the absence of history of CIS, or both </p> </li> </ul> </p> <p>The rationale underlying these subgroup analyses was as follows.</p> <p> <ul id="CD014887-list-0017"> <li> <p>Setting: per the European Organization for Research and Treatment of Cancer (EORTC) criteria, the setting of primary versus recurrent bladder cancer (primary with or without a recurrence, versus &gt; 1 recurrence) can affect the risk of recurrence and progression (<a href="./references#CD014887-bbs2-0057" title="SylvesterRJ , van derMeijdenAP , OosterlinckW ,  WitjesJA , BouffiouxC , DenisL , et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology2006;49(3):466-77. [DOI: 10.1016/j.eururo.2005.12.031]">Sylvester 2006</a>). </p> </li> <li> <p>Multifocality: per the EORTC criteria, the number of tumors (1, 2 to 7, versus ≥ 8) can affect the risk of recurrence and progression (<a href="./references#CD014887-bbs2-0057" title="SylvesterRJ , van derMeijdenAP , OosterlinckW ,  WitjesJA , BouffiouxC , DenisL , et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology2006;49(3):466-77. [DOI: 10.1016/j.eururo.2005.12.031]">Sylvester 2006</a>). </p> </li> <li> <p>Tumor size: per the EORTC criteria, the size of tumors (&lt; 3 cm versus ≥ 3 cm) can affect the risk of recurrence and progression (<a href="./references#CD014887-bbs2-0057" title="SylvesterRJ , van derMeijdenAP , OosterlinckW ,  WitjesJA , BouffiouxC , DenisL , et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology2006;49(3):466-77. [DOI: 10.1016/j.eururo.2005.12.031]">Sylvester 2006</a>). </p> </li> <li> <p>Stage: compared to other histological types, the detection of CIS is particularly difficult due to its flat growth within the cell level (<a href="./references#CD014887-bbs2-0057" title="SylvesterRJ , van derMeijdenAP , OosterlinckW ,  WitjesJA , BouffiouxC , DenisL , et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology2006;49(3):466-77. [DOI: 10.1016/j.eururo.2005.12.031]">Sylvester 2006</a>). </p> </li> </ul> </p> </section> <section id="CD014887-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>There was an insufficient number of studies to conduct sensitivity analyses to evaluate differences in methodology that could impact the results of meta‐analyses. Therefore, we could not conduct preplanned sensitivity analyses by 1) excluding studies with high risk of bias (<a href="./references#CD014887-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s).Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>), and 2) by excluding studies in which all participants underwent re‐resection on a routine basis, since routine re‐resection may mitigate potential benefits of NBI. </p> </section> <section id="CD014887-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account criteria related to internal validity (risk of bias, inconsistency, imprecision, publication bias), and external validity (directness of results) (<a href="./references#CD014887-bbs2-0035" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , SchünemannHJ , et al.GRADE: what is "quality of evidence" and why is it important to clinicians?BMJ2008;336(7651):995-8. [DOI: 10.1136/bmj.39490.551019.BE]'>Guyatt 2008</a>)<i>.</i> Two review authors (LL or GL) independently reviewed the quality of evidence for each outcome as high, moderate, low, or very low using GRADEpro GDT (<a href="./references#CD014887-bbs2-0033" title="McMaster UniversityGRADEpro GDT.Version accessed 15 September 2020. Hamilton: McMaster University, 2020. Available from www.gradepro.org.">GRADEpro GDT</a>). We resolved any discrepancies by consensus, or if needed, by arbitration with a third review author (PD). We presented a summary of the evidence in a summary of findings table, which provides key information about the best estimate of the magnitude of the effect in relative terms and absolute differences; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome (<a href="./references#CD014887-bbs2-0036" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al.GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [DOI: 10.1016/j.jclinepi.2010.04.026]">Guyatt 2011</a>; <a href="./references#CD014887-bbs2-0053" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al.Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Schünemann 2019</a>). If meta‐analysis was not possible, we planned to present data in a narrative summary of findings table. </p> <p>We presented a summary of findings table reporting the following outcomes, listed according to a priority rating established by the clinicians on our team with the input of external experts. </p> <p> <ol id="CD014887-list-0018"> <li> <p>Time to disease recurrence</p> </li> <li> <p>Time to disease progression</p> </li> <li> <p>Major adverse event</p> </li> <li> <p>Time to death from bladder cancer</p> </li> <li> <p>Minor adverse event</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014887-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014887-sec-0050"></div> <section id="CD014887-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD014887-sec-0052"> <h4 class="title">Results of the search</h4> <p>We identified 222 records during the first search in September 2020. We identified an additional 15 records during the repeated search in December 2021. After the exclusion of duplicates, we screened the title and abstract of 208 records. Of these, we deemed 160 to be irrelevant. We assessed 48 records (associated with 23 unique studies) for eligibility. Ultimately, eight randomized controlled trials, associated with 33 reports, met our inclusion criteria for the study question.  </p> <p>There were no ongoing studies nor studies awaiting classification. The details of study selection are presented as a PRISMA flow diagram in <a href="#CD014887-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD014887-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram summarizing the study screening process" data-id="CD014887-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram summarizing the study screening process</p> </div> </div> </div> </section> <section id="CD014887-sec-0053"> <h4 class="title">Included studies</h4> <p>We identified eight randomized controlled trials eligible for inclusion (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a>; <a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>; <a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). For descriptions of the included studies, see <a href="#CD014887-tbl-0002">Table 1</a> 'Overview of included studies' and <a href="./references#CD014887-sec-0106" title="">Characteristics of included studies</a>. </p> <div class="table" id="CD014887-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reference </b> </p> <p><b>identification</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Publication type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Description of participants</b> </p> <p><b>(number randomized)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator vs intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome assessed (time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Male, n (%)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2015 to 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with histopathology‐visualized non‐muscle invasive bladder cancer and complete resection of the visualized tumor </p> <p> </p> <p>(n = 158)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease recurrence (3 months)</p> <p> </p> <p>Surgical complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear. Characteristics were reported on a per‐procedure basis, and some participants had undergone more than one procedure.  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear. Characteristics were reported on a per‐procedure basis, and some participants had undergone more than one procedure.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>See above</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2013 to 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants who underwent TURBT for suspicion of a bladder tumor discovered by use of cystoscopy or another imaging study </p> <p> </p> <p>(n = 198)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of tumors identified</p> <p> </p> <p>Disease recurrence (12 months)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.96 ± 11.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>64.54 ± 12.01 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>62 (73) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with overt or suspected non‐muscle invasive bladder cancer</p> <p> </p> <p>(n = 68 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease recurrence (24 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.03 ± 12.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>63.82 ± 12.31 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> <p> </p> <p>(n = 137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Surgical complication</p> <p> </p> <p>Mean time to catheter removal</p> <p> </p> <p>Absence of muscle tissue in specimen</p> <p> </p> <p>False positive rate</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>Not reported</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2013 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants initially diagnosed with primary or recurrent non‐muscle invasive bladder cancer </p> <p> </p> <p>(n = 178)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease recurrence (3 months, 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 62 ± 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 (85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI‐guided holmium laser resection of bladder tumor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 ± 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with primary non‐muscle invasive bladder cancer</p> <p> </p> <p>(n = 965)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Surgical complication</p> <p> </p> <p>Disease recurrence (during re‐TURBT, 3 months, 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.8 ± 12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383 (80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 66.7 ± 12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>390 (81) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants from two centers with overt or suspected bladder cancer</p> <p> </p> <p>(n = 188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT: white light cystoscopy guided TURBT <i>exclusively</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Detection rate</p> <p> </p> <p>Disease recurrence</p> <p>(12 months)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.6 ± 12.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (24)</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI TURBT: NBI guided TURBT <i>exclusively</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>70.8 ± 10.3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with non‐muscle invasive bladder cancer</p> <p> </p> <p>(n = 260)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumor detection rate</p> <p> </p> <p>Surgical complication </p> <p> </p> <p>Disease recurrence (12 months, 24 months)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>64.8 (33 to 86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI‐guided bipolar plasma vaporization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>65.2 (32 to 87) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NBI: narrow band imaging; TURBT: transurethral resection of bladder tumor; WLC: white light cystoscopy </p> </div> </div> <section id="CD014887-sec-0054"> <h5 class="title">Participants</h5> <p>In total, 2152 participants were randomized. Inclusion criteria varied widely between studies. All but the study by <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a> specified their participant selection process, including participants with suspected or diagnosed non‐muscle invasive bladder cancer and excluding participants with muscle‐invasive bladder cancer. Methods used for the initial discovery of suspected bladder tumors varied from bladder lavage fluids and voided urine cytology to cystoscopies and other imaging studies. One study specified that only participants with primary bladder cancer were included (<a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>). </p> </section> <section id="CD014887-sec-0055"> <h5 class="title">Interventions</h5> <p>Transurethral resection began in the white light mode with the introduction of the resectoscope. For the control arm, participants underwent cystoscopy, tumor resection, and coagulation in the white light mode only. For the intervention arm, the instruments were originally introduced into the bladder under the white light mode, then switched to the NBI mode for cystoscopy, tumor resection, and coagulation. One study specified that the intervention was carried out entirely in the white light or NBI mode, in which switching from white light to NBI mode during the procedure was prohibited (<a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>).  One trial used holmium laser for resection (<a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>), and another used NBI‐guided bipolar plasma vaporization (<a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). </p> </section> <section id="CD014887-sec-0056"> <h5 class="title">Outcomes</h5> <p>Outcomes were measured in ranges of 3 to 35 months. The studies reporting the primary outcomes for this review were as follows. </p> <p> <ul id="CD014887-list-0019"> <li> <p>Time to disease recurrence, reported by six studies (<a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a>; <a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a>; <a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>) </p> </li> <li> <p>Time to disease progression, reported by none</p> <ul id="CD014887-list-0020"> <li> <p>No studies reported the number of participants with disease progression at 12 months or 13 to 24 months, precluding the analysis of disease progression as a dichotomous outcome. </p> </li> </ul> </li> <li> <p>Major adverse events, reported by four studies (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>) </p> </li> </ul> </p> <p>The studies reporting the secondary outcomes for this review were as follows.</p> <p> <ul id="CD014887-list-0021"> <li> <p>Time to death from bladder cancer, reported by none.</p> <ul id="CD014887-list-0022"> <li> <p>No studies reported the number of participants with bladder cancer death at 12 months or 13 to 24 months, precluding the analysis of cancer death at 12 months as a dichotomous outcome. </p> </li> </ul> </li> <li> <p>Minor adverse events, reported by four studies (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>) </p> </li> </ul> </p> </section> </section> <section id="CD014887-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded 15 reports of 15 studies. Eight were excluded for irrelevant study design (<a href="./references#CD014887-bbs2-0009" title="DoehnC , KrockenbergerK , ZumbeJ , RasslerJ , SommerauerM , FellerAC , et al.Comparison of white-light, photodynamic diagnosis and narrow-band imaging for the detection of non-muscle invasive bladder cancer: results from a randomized multicenter diagnostic phase-III study. European Urology2014;13(1):e23. [DOI: 10.1016/S1569-9056(14)60025-7]">Doehn 2014</a>; <a href="./references#CD014887-bbs2-0011" title="GeavleteB , JecuM , MultescuR , GeavleteP .Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach. Therapeutic Advances in Urology2012;4(5):211-7. [DOI: 10.1177/1756287212454181]">Geavlete 2012</a>; <a href="./references#CD014887-bbs2-0014" title="HerrH .The impact of narrow band imaging in the detection and resection of bladder tumor in transitional cell carcinoma of the bladder: a prospective, blinded, sequential intervention randomized controlled trial. Urology2019;128:60. ">Herr 2019</a>; <a href="./references#CD014887-bbs2-0018" title="MukherjeeP , GeorgeAJ , YadavBK , JeyaseelanL , KumarRM , MukhaRP , et al.The impact of narrow band imaging in the detection and resection of bladder tumor in transitional cell carcinoma of the bladder: a prospective, blinded, sequential intervention randomized controlled trial. Urology2019;128:55-60. [PMID: 30822478]">Mukherjee 2019</a>; <a href="./references#CD014887-bbs2-0019" title="NayaY , OishiM , YamadaY , UedaT , FujiharaA , NakanishiH , et al.Initial experience of combined use of photodynamic diagnosis and narrow band imaging for detection of flat urothelial lesion. International Journal of Clinical Oncology2015;20(3):593-7. [PMID: 25228479]">Naya 2015</a>; <a href="./references#CD014887-bbs2-0020" title="ShenY , ZhuY , YeD , YaoX , ZhangS , DaiB , et al.Narrow-band imaging flexible cystoscopy in the detection of new non-muscle invasive bladder cancer: a randomized study. Journal of Urology2010;183(4):e450. ">Shen 2010</a>; <a href="./references#CD014887-bbs2-0021" title='ShenYJ , ZhuYP , YeDW , YaoXD , ZhangSL , DaiB , et al.Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a "second look" matters?International Urology and Nephrology2012;44(2):451-7. [DOI: 10.1007/s11255-011-0036-5]'>Shen 2012</a>; <a href="./references#CD014887-bbs2-0023" title="YeZ , HuJ , SongX , LiF , ZhaoX , ChenS , et al.A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: a prospective, randomized and multi-center study. Scientific Reports2015;5:10905. [DOI: 10.1038/srep10905]">Ye 2015</a>). Three were excluded for irrelevant study population (<a href="./references#CD014887-bbs2-0015" title="HirnerL , StaggeE , RübbenH , SchenckM , EisenhardtA .Narrow band imaging-assisted cystoscopy in bladder tumor follow-up: can more tumors be identified?Urologe A2016;55(3):370-5. [DOI: 10.1007/s00120-015-3942-9]">Hirner 2016</a>; <a href="./references#CD014887-bbs2-0017" title="MitaK , KobatakeK , OharaS , KatoM .Clinical benefits of transurethral resection under narrow band imaging for non-muscle invasive bladder cancer. Hinyokika Kiyo2018;64(1):1-6. [DOI: 10.14989/ActaUrolJap_64_1_1]">Mita 2018</a>; <a href="./references#CD014887-bbs2-0022" title="TschirdewahnS , HarkeNN , HirnerL , StaggeE , HadaschikB , EisenhardtA .Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a randomized study in comparison with white light cystoscopy. World Journal of Urology2020;38(6):1509-15. [DOI: 10.1007/s00345-019-02926-0]">Tschirdewahn 2020</a>). Three were excluded for irrelevant study outcomes (<a href="./references#CD014887-bbs2-0010" title="DograPN , DesaiP , SinghP .Narrow band imaging cystoscopy in non-muscle invasive bladder cancer- a prospective randomized comparison to the standard white light cystoscopy. Journal of Urology2016;195(4):e137. ">Dogra 2016</a>; <a href="./references#CD014887-bbs2-0012" title="HahYS , LeeKS , KooKC , ChungBH .Identification of red/green/blue values from white-light imaging and narrow-band imaging for the discrimination of bladder cancer features. European Urology2018;17(2):e1233. [DOI: 10.1016/S1569-9056(18)31704-4]">Hah 2018</a>; <a href="./references#CD014887-bbs2-0016" title="LeeKS , KooKC , KimDK , LeeJ , KimJW , JeongJY , et al.Combination of RGB and narrow band imaging for discrimination of non-muscle invasive bladder cancer. Journal of Urology2017;197(4):e92. ">Lee 2017</a>). One was excluded because the report was retracted (<a href="./references#CD014887-bbs2-0013" title="HerrH .Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors. European Urology2015;67(4):605-8. ">Herr 2015</a>). The process of study exclusion is summarized in the PRISMA diagram. (<a href="#CD014887-fig-0001">Figure 1</a>) </p> </section> </section> <section id="CD014887-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>Visual representations of the risk of bias of the included studies are presented in <a href="#CD014887-fig-0002">Figure 2</a> and <a href="#CD014887-fig-0003">Figure 3</a>. Details are shown in <a href="./references#CD014887-sec-0106" title="">Characteristics of included studies</a>.  Since there were less than 10 included studies available for meta‐analysis, we did not create a funnel plot to assess for publication bias.  </p> <div class="figure" id="CD014887-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary" data-id="CD014887-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary</p> </div> </div> </div> <div class="figure" id="CD014887-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph" data-id="CD014887-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph</p> </div> </div> </div> <section id="CD014887-sec-0059"> <h4 class="title">Allocation</h4> <p>Six studies reported adequate efforts for random sequence generation (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a>; <a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). Two studies had no discussion of sequence generation; however, only the abstracts were available, so we deemed these to have an unclear risk of selection bias from random sequence generation (<a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>). </p> <p>Three out of eight studies reported adequate efforts to conceal allocation (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). Three full‐text studies did not describe methods used for allocation concealment, so we assessed these as having a high risk of selection bias (<a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a>; <a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>; <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>). The remaining two studies, which only provided abstracts, did not describe allocation concealment (<a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>); we rated these as having an unclear risk of selection bias.  </p> </section> <section id="CD014887-sec-0060"> <h4 class="title">Blinding</h4> <p>WLC mode and NBI mode were visually distinct. Given the nature of the intervention, no trial was able to blind the personnel involved. We considered all outcomes to be susceptible to performance bias. The risk of performance bias was high for all eight studies (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a>; <a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>; <a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>).  </p> <p>In judging the risk of detection bias, we categorized outcomes as subjective outcomes or objective outcomes. We considered time to disease recurrence and minor adverse events to be subjective outcomes, susceptible to detection bias, and grouped them together.  </p> <p>The detection of time to disease recurrence and minor adverse events involved clinical outcomes, so we considered studies that did not specify how, if any, blinding was conducted to be at high risk of detection bias for these outcomes (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a>; <a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>; <a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). One study discussed the blinding of the pathologist, which reduced the risk of detection bias for time to disease recurrence (<a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>); however, it did not state how, if any, blinding of outcome assessment for minor adverse events was conducted. As such, we judged the overall risk of detection bias to be unclear for that study. </p> <p>We considered major adverse events to be objective outcomes, not susceptible to detection bias, because no clinical judgement was involved. The risk of detection bias for major adverse events was low for all five of the studies that assessed major adverse events (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>).  </p> </section> <section id="CD014887-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>We rated the risk of attrition bias for each outcome based on the following predefined criteria: low (less than 10%), unclear (between 10% and 20%) and high (20% or higher).  </p> <p>Of the six studies that reported on time to disease recurrence or disease recurrence at 12 months or 13 to 24 months, one was at low risk of attrition bias (<a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>), one was at unclear risk of attrition bias (<a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a>), and four were at high risk of attrition bias (<a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a>; <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). </p> <p>Of the four studies that reported major and minor adverse events, one was at low risk of attrition bias (<a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>), and three were at high risk of attrition bias (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). </p> <p>In total, 2152 participants were randomized but only 1847 participants were included in our analysis. This discrepancy was due to incomplete outcome data which precluded analysis.  </p> </section> <section id="CD014887-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We assessed two studies to have a low risk of reporting bias as all outcomes were reported per trial registration (<a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>). None of the remaining studies had a trial registration or protocol available for comparison, so we assessed these to have an unclear risk of reporting bias.  </p> </section> <section id="CD014887-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify other potential sources of bias. </p> </section> </section> <section id="CD014887-sec-0064"> <h3 class="title" id="CD014887-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD014887-tbl-0001"><b>Summary of findings 1</b> NBI + WLC TURBT compared to WLC TURBT for transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer</a> </p> <section id="CD014887-sec-0065"> <h4 class="title">NBI versus white light cystoscopy alone for transurethral resection </h4> <p>See: <a href="./full#CD014887-tbl-0001">summary of findings Table 1</a> </p> <section id="CD014887-sec-0066"> <h5 class="title">Primary outcomes</h5> <section id="CD014887-sec-0067"> <h6 class="title">Time to disease recurrence (time‐to‐event)</h6> <p>Based on six studies involving 1244 participants that reported time to disease recurrence (<a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a>; <a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a>; <a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>), NBI + WLC TURBT may lower the risk of disease recurrence over time compared to WLC TURBT (hazard ratio 0.63 in favor of the NBI + WLC TURBT group, 95% CI 0.45 to 0.89; I<sup>2</sup> = 53%; low certainty of evidence; <a href="./references#CD014887-fig-0004" title="">Analysis 1.1</a>). The anticipated absolute effects varied depending on the baseline risk of recurrence. For the low‐risk population, the use of NBI + WLC TURBT corresponded to 53 fewer (range: 79 fewer to 15 fewer) recurrences per 1000 participants at 12 months. For the high‐risk population, the use of NBI + WLC TURBT corresponded to 163 fewer (range: 265 fewer to 43 fewer) recurrences per 1000 participants at 12 months. The point estimates and confidence intervals for absolute effects did not meet the previously established thresholds of clinically relevant difference decrease (5% or more). All data were extrapolated from Kaplan‐Meier curves or outcomes data according to the Tierney method (<a href="./references#CD014887-bbs2-0058" title="TierneyJF , StewartLA , GhersiD , BurdettS , Sydes MR .Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(16):1-16. [DOI: 10.1186/1745-6215-8-1]">Tierney 2007</a>). </p> </section> <section id="CD014887-sec-0068"> <h6 class="title">Disease progression (time‐to‐event or dichotomous)</h6> <p>No studies reported data on disease progression. </p> </section> <section id="CD014887-sec-0069"> <h6 class="title">Major adverse event (Clavien‐Dindo III, IV, V) (dichotomous)</h6> <p>Four studies involving 1385 participants reported on the occurrence of major adverse events. There were no major adverse events reported among either the NBI + WLC TURBT group or the WLC TURBT group in three of the four studies (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). One study found 16 major adverse events among 484 participants who underwent NBI + WLC TURBT and nine major adverse events among 481 participants who underwent WLC TURBT (<a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>) Considered together, there may be little to no difference in the risk of major adverse events between the two groups (risk ratio 1.77, 95% CI 0.79 to 3.96; calculated from 1 study  (<a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>) with 965 participants; low certainty of evidence; <a href="./references#CD014887-fig-0005" title="">Analysis 1.2</a>). The anticipated absolute effect was 10 more (range: 3 fewer to 39 more) major adverse events per 1000 participants. The point estimates and confidence intervals did not meet the previously established thresholds of clinically relevant difference for major adverse events (2% or more).  </p> </section> </section> <section id="CD014887-sec-0070"> <h5 class="title">Secondary outcomes</h5> <section id="CD014887-sec-0071"> <h6 class="title">Death from bladder cancer (time‐to‐event or dichotomous)</h6> <p>No studies reported data on death from bladder cancer. </p> </section> <section id="CD014887-sec-0072"> <h6 class="title">Minor adverse event (Clavien‐Dindo I, II) (dichotomous)</h6> <p>Four studies involving 1385 participants reported on the occurrence of minor adverse events. All four studies had at least one minor adverse event in either the NBI + WLC TURBT group or the WLC TURBT group (<a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a>; <a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a>; <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>; <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). There were 78 minor adverse events among 704 participants who underwent NBI + WLC TURBT and 77 minor adverse events among 681 participants who underwent WLC TURBT. Considered together, there may be little to no difference in the risk of minor adverse events between the two groups (risk ratio 0.88, 95% CI 0.49 to 1.56; I<sup>2</sup> = 61%; 4 studies, 1385 participants; low certainty of evidence; <a href="./references#CD014887-fig-0006" title="">Analysis 1.3</a>). The anticipated absolute effect was 14 fewer (range: 58 fewer to 63 more) minor adverse events per 1000 participants. The point estimates and confidence intervals did not meet the previously established thresholds of clinically relevant difference for minor adverse events (5% or more).  </p> </section> </section> <section id="CD014887-sec-0073"> <h5 class="title">Subgroup Analysis</h5> <p>There were insufficient data available to conduct our planned subgroup analysis. </p> </section> <section id="CD014887-sec-0074"> <h5 class="title">Sensitivity Analysis</h5> <p>There were no full‐text studies free of high risk of bias for all domains, precluding the ability to perform our prespecified sensitivity analyses.  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014887-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014887-sec-0075"></div> <section id="CD014887-sec-0076"> <h3 class="title" id="CD014887-sec-0076">Summary of main results</h3> <p>In total, we identified eight randomized controlled trials, involving 2152 participants with suspected or diagnosed non‐muscle invasive bladder cancer, that compared NBI + WLC TURBT with WLC TURBT in the treatment of primary or recurrent non‐muscle invasive bladder cancer. Of the 2152 participants randomized, we included 1847 participants in the analysis. The discrepancy between participants randomized and those analyzed was most commonly due to incomplete outcome data.  </p> <p>Based on limited time‐to‐event data, the addition of NBI + WLC TURBT may lower the risk of disease recurrence over time. We were not able to examine death from bladder cancer as a time‐to‐event outcome or a dichotomous outcome. Our analysis suggests that there is no difference in risk of major or minor adverse events between the two groups. However, the certainty of evidence was low. </p> <p>Given the limited data available, subgroup analysis and sensitivity analysis were not possible. </p> </section> <section id="CD014887-sec-0077"> <h3 class="title" id="CD014887-sec-0077">Overall completeness and applicability of evidence</h3> <p>This Cochrane Review is based on eight randomized controlled trials published between 2009 and 2017. The studies included participants undergoing transurethral resection of bladder tumor for suspected or pathologically confirmed (primary or recurrent), non‐muscle invasive bladder cancer (stage Ta, T1, and carcinoma in situ). This population is consistent with our inclusion criteria and represents a clinically relevant cohort for the use of NBI + WLC TURBT.  </p> <p>All but one study compared NBI + WLC TURBT to WLC TURBT alone. One study (<a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>) compared NBI TURBT alone to WLC TURBT alone. We expect the results from this study to provide more conservative estimates for time to disease recurrence (favoring the null), since surgeons would be performing cystoscopy with only one light source (NBI) rather than with two light sources (NBI + WLC), which would theoretically lead to less opportunity for disease detection. We expect that the intervention of NBI TURBT alone vs WLC TURBT alone would underreport adverse events (favoring safety), since only one light source is used to examine the bladder. However, this particular study did not contribute data to adverse events, so our estimates are unchanged (<a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>). </p> <p>The majority of studies compared NBI + WLC TURBT with WLC TURBT alone using electrocautery to resect tumors, though one used laser resection of bladder tumor (<a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a>), and another used bipolar plasma vaporization (<a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a>). The influence on the type of resection of tumor performed on our outcomes is unknown and may introduce heterogeneity to our results. In addition to this, the type of WLC used (high definition versus standard definition) was not routinely described, and may influence the ability to detect tumors with WLC and the outcomes of the studies. The applicability of the intervention is improved by the fact that narrow band imaging is a standardized technology, though many differing manufacturers produce endoscopic cameras capable of NBI and not all studies described the NBI system they used.   </p> <p>Variation in the clinical management of people with non‐muscle invasive bladder cancer introduced heterogeneity and decreased the applicability of our results. For example, the use of immediate (within 24 hours of TURBT) postoperative chemotherapy instillations and intravesical therapy was not consistent between studies, so we could not include this in the analysis. Studies varied in their administration of mitomycin‐C, doxirubicin or epirubicin in the immediate (24‐hour) postoperative period and in the intravesical therapy regimens people with non‐muscle invasive bladder cancer may have received. In addition, the inclusion of people who underwent repeat transurethral resection and the timing of these resections were not well described and were likely to have been inconsistent between studies. These differences may impact the clinical applicability of our study results. </p> <p>It is also important to discuss that the benefit of NBI + WLC TURBT on time to disease recurrence on clinical outcomes may be due to the fact that increased detection of tumors may lead to escalation of risk stratification, which then leads to more aggressive observation schedules and interventions. Therefore, the impact of NBI on disease recurrence may be indirect, through this cascade.   </p> </section> <section id="CD014887-sec-0078"> <h3 class="title" id="CD014887-sec-0078">Quality of the evidence</h3> <p>We assessed the certainty of evidence using the GRADE approach, and considered it to be low for all outcomes. We consistently downgraded the certainty for risk of bias and imprecision. </p> <p> <ul id="CD014887-list-0023"> <li> <p>Risk of bias: due to the nature of TURBT, personnel could not be blinded to treatment assignment. We considered the risk of performance bias for all outcomes, and the risk of detection bias for susceptible outcomes (i.e. time to disease recurrence, minor adverse events) to be high. However, we would not expect the lack of blinding to bias the detection of major adverse events because no clinical judgement would be involved. We downgraded the certainty of evidence by one level for issues of performance bias, detection bias, incomplete outcome data, or selective reporting. </p> </li> <li> <p>Imprecision: we downgraded the certainty of evidence based on the confidence interval around the effect size, and whether it included both clinically relevant potential benefit and harm. </p> </li> </ul> </p> </section> <section id="CD014887-sec-0079"> <h3 class="title" id="CD014887-sec-0079">Potential biases in the review process</h3> <p>Few studies presented time to disease recurrence; among these, all data were presented in the form of Kaplan‐Meier curves or dichotomous outcome data only. We contacted all study authors to request additional data via email, but did not receive any additional data. Therefore, we derived hazard ratios for the outcome of time to disease recurrence based on dichotomous outcome data and Kaplan‐Meier curves, according to the Tierney method (<a href="./references#CD014887-bbs2-0058" title="TierneyJF , StewartLA , GhersiD , BurdettS , Sydes MR .Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(16):1-16. [DOI: 10.1186/1745-6215-8-1]">Tierney 2007</a>). This method can only reconstruct hazard ratios according to the information available and may have resulted in bias.   </p> <p>There were no data available on time to disease progression or time to death from bladder cancer, nor were dichotomous outcomes (disease progression, death from bladder cancer) reported. </p> </section> <section id="CD014887-sec-0080"> <h3 class="title" id="CD014887-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>Several systematic reviews have been performed on the topic of NBI + WLC TURBT for non‐muscle invasive bladder cancer. They are listed chronologically with a brief discussion on the conclusions of each review. </p> <p> <ul id="CD014887-list-0024"> <li> <p><a href="./references#CD014887-bbs2-0044" title="LeeJY , ChoKS , KangDH , JungHD , KwonJK , OhCK , et al.A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection in patients with non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence versus hexylaminolevulinate fluorescence versus narrow band imaging. BMC Cancer2015;15:1-10. [DOI: 10.1186/s12885-015-1571-8]">Lee 2015</a> performed a systematic review and network meta‐analysis on the use of blue light‐guided or NBI + WLC TURBT versus WLC TURBT alone. Of the 15 studies included, four were trials comparing NBI + WLC TURBT to WLC TURBT alone. Our review included three of the four trials included in their review (<a href="./references#CD014887-bbs2-0011" title="GeavleteB , JecuM , MultescuR , GeavleteP .Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach. Therapeutic Advances in Urology2012;4(5):211-7. [DOI: 10.1177/1756287212454181]">Geavlete 2012</a>, which was an earlier publication for the <a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a> trial, <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>, <a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a>). The remaining trial violated the randomization requirement (i.e. participants were consecutively enrolled) for eligibility of inclusion for our review. The authors used the Cochrane risk of bias assessment but did not grade certainty of evidence. Consistent with the directionality we found in our study, which favored NBI + WLC TURBT for decreasing disease recurrence at 12 months, the authors found that NBI + WLC TURBT was superior to that using WLC, with an odds ratio (OR) of 0.47 (95% CI 0.31 to 0.72; P  &lt;  0.001) for the outcome of recurrence rate, which was defined as the number of bladder cancer recurrences after initial TURBT. </p> </li> <li> <p><a href="./references#CD014887-bbs2-0042" title="KangW , CuiZ , ChenQ , ZhangD , ZhangH , Jin X.Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis. Oncotarget2017;8(14):23880-90. [DOI: 10.18632/oncotarget.13054]">Kang 2017</a> performed a systematic review of six studies on the use of NBI in reducing recurrence risk (dichotomous outcome at three months, one year, and two years). Of these, one was retrospective, and one prospective study has subsequently been retracted; we included all four eligible randomized controlled trials in this Cochrane Review. The authors used the Cochrane risk of bias tool and found that all RCTs were at high risk of performance bias and low or unclear risk of other forms of bias. The certainty of evidence was not evaluated. Kang and colleagues found that NBI + WLC TURBT was associated with improvements in the three‐month recurrence risk (relative risk [RR] 0.39, 95% CI 0.26 to 0.60; P &lt; 0.0001), one‐year recurrence risk (RR 0.52, 95% CI 0.40 to 0.67; P &lt; 0.00001) and two‐year recurrence risk (RR 0.60, 95% CI 0.42 to 0.85; P = 0.004) compared with WLC TURBT. </p> </li> <li> <p><a href="./references#CD014887-bbs2-0060" title="Xiong Y, LiJ , MaS , GeJ , ZhouL , LiD , et al.A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS ONE2017;12(2):e0170819. [DOI: 10.1371/journal.pone.0170819]">Xiong 2017</a> performed a systematic review of 25 studies, including 17 full texts and eight abstracts, to compare NBI + WLC TURBT with WLC TURBT alone in detection and recurrence risk. The meta‐analysis included both randomized and non‐randomized studies. In the risk of recurrence assessment, six studies were included, three of which were not randomized controlled trials. The study used the Quality Assessment of Diagnostic Accuracy Studies‐2 (QUADAS‐2) to assess the quality and risk of bias of the studies included in their review. The QUADAS‐2 only assesses four domains (participant selection, index test, reference standard, and flow and timing) versus the Cochrane risk of bias tool, which assesses six domains (selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias). Furthermore, Cochrane uses the GRADE approach to assess the quality of evidence. Consistent with our review, the authors found that NBI significantly reduced the recurrence rate of bladder cancer with a pooled risk ratio of 0.43 (95% CI 0.23 to 0.79) and 0.81 (95% CI 0.69 to 0.95) at three months and 12 months, respectively. </p> </li> <li> <p><a href="./references#CD014887-bbs2-0028" title="Chen C,  Feng S,  Hao L, ThomasL , HuangJ , LinT .Comparative efficacy of new technology-assisted transurethral resection of patients with non-muscle invasive bladder cancer: systematic review and Bayesian network meta-analysis. International Journal of Urology2017;24:33. [DOI: 10.1111/iju.13413]">Chen 2017</a> performed a systematic review inclusive of 22 trials with a total of 7767 participants to assess the use of NBI and/or blue light TURBT relative to WLC TURBT alone. We were only able to locate an abstract and found no corresponding manuscript, so we were not able to discern the number of studies that were relevant to our outcomes of interest and compare methodology. Their outcomes of interest were one‐year, two‐year, and five‐year recurrence rates and progression rate, assessed with odds ratios. The authors found that the use of NBI + WLC TURBT was associated with lower odds of recurrence at one year (OR 0.56, 95% CI 0.31 to 0.91), compared to WLC TURBT. They reported that the use of NBI + WLC TURBT was associated with lower two‐year and five‐year recurrence rates, though odds ratios were not available. In addition, the authors concluded that NBI + WLC TURBT had "the higher probabilities to be the best intervention in lower 1‐year, 2‐year and 5‐ year recurrence rate" relative to WLC TURBT. </p> </li> <li> <p><a href="./references#CD014887-bbs2-0048" title="MotlaghR , MoriK , LaukhtinaE , AydhA , KatayamaS , GrossmannN , et al.Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials. British Journal of Urology International2021;128(3):280-9. [DOI: 10.1111/bju.15383] [PMID: 33683778]">Motlagh 2021</a> performed a systematic review and Bayesian sensitivity network meta‐analysis of randomized trials, comparing the recurrence rates among the intervention group undergoing 1) blue light guided‐TURBT with or without single immediate intravesical chemotherapy, 2) NBI + WLC TURBT with or without single immediate intravesical chemotherapy, or 3) WLC TURBT with single immediate intravesical chemotherapy and the control group undergoing WLC TURBT alone. The authors concluded that NBI, with or without single immediate intravesical chemotherapy, was not associated with a significantly lower likelihood of 12‐month recurrence rate (OR 0.39, 95% CI 0.11 to 1.29; OR 0.65, 95% CI 0.343 to 1.15, respectively). </p> </li> <li> <p><a href="./references#CD014887-bbs2-0034" title="GravestockP , CoulthardN , VeeratterapillayR , HeerR .Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer. International Journal of Urology2021;28:1212-7. [DOI: 10.1111/iju.14671]">Gravestock 2021</a> performed a systematic review inclusive of three trials with a total of 921 participants to assess the effect of NBI + WLC TURBT compared with white light on recurrence rates in NMIBC. Our review included three of the three trials included in their review (<a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a>, <a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>, <a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a>). Their outcomes of interest were recurrence at 12 and 24 months and adverse events. The authors did not find a statistically significant result. However, the analysis showed a trend in favor of NBI + WLC TURBT with a risk ratio of 0.75 (95% CI 0.50 to 1.14; P = 0.18; I<sup>2</sup> = 61%). The authors also reported that only one of the included studies (<a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a>) reported on adverse events and no significant difference was observed between the two cohorts. </p> </li> </ul> </p> <p>In summary, several existing systematic reviews support a positive or neutral effect of NBI + WLC TURBT on reducing the risk of recurrence. Our rigorous inclusion of only randomized controlled trial data, extrapolation of time‐to‐event data, more recent systematic review, and assessment of the certainty of evidence rating on a per outcome basis distinguished our review from prior reviews. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014887-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/urn:x-wiley:14651858:media:CD014887:CD014887-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram summarizing the study screening process" data-id="CD014887-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_t/tCD014887-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram summarizing the study screening process</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014887-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/urn:x-wiley:14651858:media:CD014887:CD014887-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary" data-id="CD014887-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_t/tCD014887-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014887-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/urn:x-wiley:14651858:media:CD014887:CD014887-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph" data-id="CD014887-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_t/tCD014887-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014887-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/urn:x-wiley:14651858:media:CD014887:CD014887-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NBI + WLC TURBT vs WLC TURBT alone, Outcome 1: Time to disease recurrence " data-id="CD014887-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_t/tCD014887-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: NBI + WLC TURBT vs WLC TURBT alone, Outcome 1: Time to disease recurrence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/references#CD014887-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014887-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/urn:x-wiley:14651858:media:CD014887:CD014887-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NBI + WLC TURBT vs WLC TURBT alone, Outcome 2: Major adverse event (Clavien‐Dindo III, IV, V)" data-id="CD014887-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_t/tCD014887-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: NBI + WLC TURBT vs WLC TURBT alone, Outcome 2: Major adverse event (Clavien‐Dindo III, IV, V) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/references#CD014887-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014887-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/urn:x-wiley:14651858:media:CD014887:CD014887-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NBI + WLC TURBT vs WLC TURBT alone, Outcome 3: Minor adverse event (Clavien‐Dindo grade I, II)" data-id="CD014887-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_t/tCD014887-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: NBI + WLC TURBT vs WLC TURBT alone, Outcome 3: Minor adverse event (Clavien‐Dindo grade I, II) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/references#CD014887-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/media/CDSR/CD014887/image_n/nCD014887-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014887-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">NBI + WLC TURBT compared to WLC TURBT for transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NBI + WLC TURBT compared to WLC TURBT for transurethral resection of bladder tumors in people with non‐muscle invasive bladder cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer<br/><b>Setting:</b> outpatient or inpatient setting<br/><b>Intervention:</b> NBI + WLC TURBT<br/><b>Comparison:</b> WLC TURBT  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with WLC TURBT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with NBI + WLC TURBT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Time to disease recurrence</b> </p> <p> </p> <p>Follow‐up: range 12 months to 35 months</p> <p> </p> <p>Assumed MCID: 5% (absolute effect size estimate based on events at 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>1244<br/>(6 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.63<br/>(0.45 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In the low risk population, NBI + WLC TURBT may lower the risk of disease recurrence over time. We have limited confidence about this finding. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 fewer per 1000<br/>(79 fewer to 15 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>In the high risk population, NBI + WLC TURBT may lower the risk of disease recurrence over time. We have limited confidence about this finding. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>610 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 fewer per 1000<br/>(265 fewer to 43 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to disease progression</b>  </p> <p> </p> <p>Follow‐up: not applicable</p> <p> </p> <p>Assumed MCID: 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no data on time to disease progression.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse event</b> (Clavien‐Dindo grade III, IV, and V) </p> <p> </p> <p>Follow‐up: range 3 months to 24 months</p> <p> </p> <p>Assumed MCID: 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1385<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.77<br/>(0.79 to 3.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NBI + WLC TURBT may have little to no effect on major adverse events. We have limited confidence about this finding. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 more per 1000<br/>(3 fewer to 39 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to death from bladder cancer</b> </p> <p> </p> <p>Follow‐up: not applicable</p> <p> </p> <p>Assumed MCID: 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no data on time to death from bladder cancer.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor adverse event</b> (Clavien‐Dindo grade I and II) </p> <p> </p> <p>Follow‐up: range 3 months to 24 months</p> <p> </p> <p>Assumed MCID: 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1385<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.49 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NBI + WLC TURBT may have little to no effect on the risk of a minor adverse event. We have limited confidence about this finding. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 fewer per 1000<br/>(58 fewer to 63 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MCID:</b> minimal clinically important difference; <b>NBI:</b> narrow band imaging; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>TURBT:</b> transurethral resection of bladder tumor; <b>WLC:</b> white light cystoscopy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We rated down by one level for study limitations due to unclear or high risk of bias.<br/><sup>b</sup>We rated down by one level for imprecision given few events, wide confidence intervals, or both.<br/><sup>c</sup>The recurrence rate after TURBT for participants with non‐muscle invasive bladder cancer is highly variable in the literature. Among the pooled cohort of 2596 participants from seven European Organization for Research and Treatment of Cancer clinical trials, the probabilities of recurrence at one year after TURBT ranged from 15% to 61% (<a href="./references#CD014887-bbs2-0057" title="SylvesterRJ , van derMeijdenAP , OosterlinckW ,  WitjesJA , BouffiouxC , DenisL , et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology2006;49(3):466-77. [DOI: 10.1016/j.eururo.2005.12.031]">Sylvester 2006</a>). Therefore, we considered 15% as low risk and 61% as high risk.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">NBI + WLC TURBT compared to WLC TURBT for transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014887-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reference </b> </p> <p><b>identification</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Publication type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Description of participants</b> </p> <p><b>(number randomized)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator vs intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome assessed (time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Male, n (%)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0001" title="BuabanK , AttawettayanonW , SirisreetreeruxP , ViseshsindhW , KijvikaiK , KongcharoensombatW , et al.Comparison of 3-month recurrence rates after white-light versus narrow-band imaging transurethral resection for non-muscle invasive bladder cancer: a prospective, randomized control trial. Journal of the Medical Association of Thailand2018;101(4):463-9. ">Buaban 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2015 to 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with histopathology‐visualized non‐muscle invasive bladder cancer and complete resection of the visualized tumor </p> <p> </p> <p>(n = 158)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease recurrence (3 months)</p> <p> </p> <p>Surgical complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear. Characteristics were reported on a per‐procedure basis, and some participants had undergone more than one procedure.  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear. Characteristics were reported on a per‐procedure basis, and some participants had undergone more than one procedure.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>See above</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0002" title="KimSB , YoonSG , TaeJ , KimJY , ShimJS , KangSG , et al.Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investigative and Clinical Urology2018;59(2):98-105. ">Kim 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2013 to 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants who underwent TURBT for suspicion of a bladder tumor discovered by use of cystoscopy or another imaging study </p> <p> </p> <p>(n = 198)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of tumors identified</p> <p> </p> <p>Disease recurrence (12 months)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.96 ± 11.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>64.54 ± 12.01 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>62 (73) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0003" title="LeeJY , ChoiJH , KimIK , JungHD , KangHW , LeeKS , et al.Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: a randomized control trial, pilot study. Journal of Urology2014;191(4):e240-1. ">Lee 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with overt or suspected non‐muscle invasive bladder cancer</p> <p> </p> <p>(n = 68 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease recurrence (24 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.03 ± 12.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>63.82 ± 12.31 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0004" title="LongoF , DelorM , MangiarottiB , Del NeroA , MontanariE .Feasibility of transurethral resection of the bladder (TURB) done by narrow-band imaging (NBI). European Urology2013;12(1):e596. ">Longo 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> <p> </p> <p>(n = 137)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Surgical complication</p> <p> </p> <p>Mean time to catheter removal</p> <p> </p> <p>Absence of muscle tissue in specimen</p> <p> </p> <p>False positive rate</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>Not reported</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0005" title="MaT , WangW , JiangZ , ShaoG , GuoL , LiJ , et al.Narrow band imaging-assisted holmium laser resection reduced the recurrence rate of non-muscle invasive bladder cancer: a prospective, randomized controlled study. National Medical Journal of China2015;95(37):3032-5. TianjiaM , JunjiaL , ZhaoqunJ , WenzhenW , GuangfengS , LeiZ , et al.Narrow band imaging-assisted holmium laser resection reduces the residual tumor rate of primary non-muscle invasive bladder cancer; a comparison with the standard approach. National Medical Journal of China2015;95(34):2775-8. ">Ma 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2013 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants initially diagnosed with primary or recurrent non‐muscle invasive bladder cancer </p> <p> </p> <p>(n = 178)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease recurrence (3 months, 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 62 ± 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 (85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI‐guided holmium laser resection of bladder tumor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 ± 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0006" title="dela RosetteJ , GravasS .A multi-center, randomized international study to compare the impact of narrow band imaging versus white light cystoscopy in the recurrence of bladder cancer. Journal of Endourology2010;24(5):660-1. Japan Primary Registries Network UMIN000004545.A multi-centre, international study to compare use of narrow band imaging (NBI) versus white light imaging (WLI) during TURBT to assess recurrence of bladder cancer in terms of safety and efficacy. trialsearch.who.int/?TrialID=JPRN-UMIN000004545 (first received 15 November 2010). NaitoS , AlgabaF , BabjukM , BryanRT , SunYH , ValiquetteL , et al.The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. European Urology2016;70(3):506-15. NCT01180478.Comparison study of narrow band imaging versus white light resection in patients with bladder tumors/cancer. clinicaltrials.gov/show/NCT01180478 (first received 12 August 2010). NTR3645.The Global Randomized NBI Bladder Cancer Study- a multi-centre, international study to compare use of narrow band imaging (NBI) versus white light (WL) during TURB to assess recurrence of bladder cancer in terms of safety and efficacy. trialregister.nl/trial/3513 (first received 10 February 2012). ">Naito 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with primary non‐muscle invasive bladder cancer</p> <p> </p> <p>(n = 965)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Surgical complication</p> <p> </p> <p>Disease recurrence (during re‐TURBT, 3 months, 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.8 ± 12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383 (80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI + WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 66.7 ± 12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>390 (81) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0007" title="IntroiniC , NaselliA , TimossiL , PuppoP , GerminaleF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. Anticancer Research2012;32(5):1907. NaselliA , IntroiniC , BertolottoF , SpinaB , PuppoP .Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. Journal of Endourology2010;24(7):1131-4. [PMID: 20509796]NaselliA , IntroiniC , GerminaleF , BertolottoF .A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on non muscle invasive bladder cancer recurrence. European Urology Supplements2012;11(1):e960. NaselliA , IntroiniC , TimossiL , SpinaB , FontanaV , PezziR , et al.A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European Urology2012;61(5):908-13. NCT01004211.Prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging. clinicaltrials.gov/ct2/show/NCT01004211 (first received 29 October 2009). PuppoP , IntroiniC , GerminaleF , NaselliA .Is it possible to avoid second TUR in high grade bladder cancer after a first TUR performed in NBI modality?Journal of Endourology2011;25:A130. [EMBASE: 70585038]PuppoP , IntroiniC , GerminaleF , NaselliA .Randomized prospective trial to assess impact of TUR in narrow band imaging on non muscle invasive bladder cancer recurrence. Journal of Endourology2011;25:A302. ">Naselli 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants from two centers with overt or suspected bladder cancer</p> <p> </p> <p>(n = 188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT: white light cystoscopy guided TURBT <i>exclusively</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Detection rate</p> <p> </p> <p>Disease recurrence</p> <p>(12 months)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.6 ± 12.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (24)</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI TURBT: NBI guided TURBT <i>exclusively</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>70.8 ± 10.3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD014887-bbs2-0008" title="GeavleteB , MultescuR , GeorgescuD , MoldoveanuC , StanescuF , JecuM , et al.The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases - a prospective, randomized controlled comparison to the standard management. European Urology Supplements2014;13(5):105-6. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , GeavleteP .Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology2012;79(4):846-51. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. European Urology Supplements2013;12(4):e1229. GeavleteB , MultescuR , GeorgescuD , StanescuF , JecuM , MoldoveanuC , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases - a prospective, randomized comparison to the standard approach. Journal of Endourology2013;27:A151. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors: results of a prospective, randomized, long-term comparison to the standard approach. Urology2011;78(3):S18-9. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long term comparison to the standard approach. European Urology Supplements2011;10(2):181. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , GeavleteP .Bipolar plasma vaporization and NBI for large non-muscle invasive bladder tumors - results of a prospective, randomized, long-term comparison to the standard approach. Journal of Urology2011;185(4):e663. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. European Urology Supplements2012;11(1):E959-U15. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar resection in cases of large non-muscle invasive bladder tumors - a prospective, randomized, long term study. Journal of Urology2012;187(4):E673. GeavleteB , MultescuR , StanescuF , GeorgescuD , JecuM , MoldoveanuC , et al.NBI cystoscopy and bipolar plasma vaporization versus standard cystoscopy and monopolar TURBT in cases of large non-muscle invasive bladder tumors. Journal of Endourology2011;25:A140. GeavleteB , MultescuR , StanescuF , JecuM , GeorgescuD , IacoboaieC , GeavleteP .Combined narrow band imaging cystoscopy in cases of large non-muscle invasive bladder tumors - better than the standard approach?Journal of Endourology2012;26(Suppl 1):A92-3. GeavleteB , StanescuF , JecuM , MoldoveanuC , MultescuR , GeorgescuD , et al.Combined narrow band imaging cystoscopy and bipolar plasma vaporization in cases of large non-muscle invasive bladder tumors - better than the standard approach?European Urology2012;11(4):89. [DOI: 10.1016/S1569-9056(13)60032-9]GeavleteB , StanescuF , MultescuR , GeorgescuD , MoldoveanuC , JecuM , et al.Three-year impact of combined narrow band imaging cystoscopy and bipolar plasma vaporization in large non-muscle invasive bladder tumors' cases-a prospective, randomized comparison to the standard approach. Journal of Urology2013;189(4):e523. GeavleteBF , MultescuRD , GeorgescuDA , JecuM , StanescuFA , MoldoveanuC , et al.Comparative therapeutic impact and long-term NMIBC recurrence rates specific for HAL blue light cystoscopy, combined NBI-bipolar plasma vaporization and the standard approach in randomized clinical settings. European Urology Supplements2013;12(1):e570. StănescuF , GeavleteB , GeorgescuD , JecuM , MoldoveanuC , AdouL , et al.NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management. Journal of Medicine and Life2014;7(2):155-9. ">Stănescu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with non‐muscle invasive bladder cancer</p> <p> </p> <p>(n = 260)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLC TURBT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumor detection rate</p> <p> </p> <p>Surgical complication </p> <p> </p> <p>Disease recurrence (12 months, 24 months)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>64.8 (33 to 86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NBI‐guided bipolar plasma vaporization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>65.2 (32 to 87) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>NBI: narrow band imaging; TURBT: transurethral resection of bladder tumor; WLC: white light cystoscopy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/full#CD014887-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014887-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NBI + WLC TURBT vs WLC TURBT alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Time to disease recurrence  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.45, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Major adverse event (Clavien‐Dindo III, IV, V) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.79, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Minor adverse event (Clavien‐Dindo grade I, II) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.49, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NBI + WLC TURBT vs WLC TURBT alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014887.pub2/references#CD014887-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014887.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD014887-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD014887-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014887-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014887-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD014887-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD014887-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD014887-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD014887-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014887-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014887-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014887\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014887\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014887\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014887\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014887\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014887.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014887.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014887.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014887.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014887.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714290275"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014887.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714290278"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014887.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6b126f07f3cd',t:'MTc0MDcxNDI5MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 